This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race secures sixth US patent for Zantrene
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF
19 October 2021 – Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US patent no. 11,147,800) on its cancer drug, Zantrene® (bisantrene dihydrochloride), by the United States Patent and Trademarks Office (USPTO). This patent expires on 25 July 2034.
This is Race’s sixth granted patent on Zantrene in the United States.
“The new US patent provides Race with further protection around uses of Zantrene (and related chemical structures) that improve the efficacy of Zantrene treatments”
Race’s CEO Phillip Lynch
This new patent further expands the therapeutic utility of Zantrene (and related chemical structures), in particular – methods that improve the therapeutic efficacy of Zantrene and reduce side effects.
The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192), 2020 (US 10,548,876) and in 2021 (US 11,135,201), further strengthening Race’s growing IP position for Zantrene.